新生儿无乳链球菌的耐药性分析

Analysis of Drug Resistance of Streptococcus agalactiae in Neonates

目的分析某综合医院新生儿无乳链球菌(Streptococcus agalactiae)检出及其耐药情况,为临床医生治疗新生儿无乳链球菌抗感染提供依据。方法选取2017年1月—2022年12月医院新生儿科无乳链球菌分离株。所有菌株经BD PhoenixTM-100型全自动微生物分析仪或纸片扩散法进行药物敏感实验。结果2017年—2022年,新生儿科累计住院人数总数为16772人,共检出无乳链球菌243株。来源于胃液分泌物标本186株,占76.54%,其次为血液标本51株,占20.99%;无乳链球菌感染女性新生儿人数略高于男性;无乳链球菌的药敏试验显示菌株对氨苄西林、头孢吡肟、利奈唑胺、美罗培南、青霉素和万古霉素尚未耐药。红霉素六年耐药率均大于57.1%;四环素六年耐药率均大于64.7%,总耐药率在73.8%;左氧氟沙星六年耐药率在25.5%~42.9%,总耐药率在31.4%。结论为临床儿科医生进行有效的抗感染预防和治疗提供重要的依据,同时有助于降低新生儿不良反应的风险。

Objective To analyze the detection of Streptococcus agalactiae(Group B Streptococcus)and its drug resistance in neonates within a general hospital.This analysis aims to provide clinicians with valuable insights for treating neonatal Streptococcus agalactiae infections effectively.Methods Between January 2017 and December 2022,isolates of Streptococcus agalactiae were obtained from the hospital's neonatal unit.All strains underwent drug susceptibility testing using the BD PhoenixTM-100 fully automated microbiology analyzer or the paper diffusion method.Results Over the period of 2017 to 2022,the neonatal unit recorded a total of 16,772 hospitalizations,among which 243 strains of Streptococcus agalactiae were identified.Gastric fluid secretion specimens accounted for 76.54%(186 strains),followed by blood specimens at 20.99%(51 strains).The number of Streptococcus agalactiae infections was slightly higher in female neonates compared to males.Drug susceptibility testing revealed that strains showed no resistance to ampicillin,cefepime,linezolid,meropenem,penicillin,and vancomycin.However,erythromycin had a resistance rate of more than 57.1%over the six-year period;tetracycline had a resistance rate of more than 64.7%over the same period,totaling 73.8%;and levofloxacin had a six-year resistance rate ranging from 25.5%to 42.9%,with an overall resistance rate of 31.4%.Conclusion This work provides a critical basis for the prevention and management of Streptococcus agalactiae infections in neonates.It aims to assist pediatric clinicians in minimizing the risk of adverse outcomes in neonatal care.